Discover nano2026ReviewNon-viral Gene DeliveryDrug Delivery
Aadil Kr, Bhange K, Kommineni N, Mishra G, Bunekar N, Jha A, Et Al.
Messenger RNA (mRNA)-based therapeutics have transformed cancer treatment strategies, especially after the success of lipid nanoparticle (LNP)-enabled mRNA vaccines. LNPs are effective non-viral delivery vehicles that protect mRNA, enhance intracellular delivery, and improve therapeutic safety. This review discusses…
Read the article →Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2026ReviewNon-viral Gene Delivery
Schauberger Em, Phillips Ja
The management of allergic and immunologic diseases has long centered on symptom management rather than disease modification. Conventional pharmacotherapy controls manifestations of the immune dysregulation but does little to treat the underlying cause. Newer monoclonal and small molecule therapies target downstream…
Read the article →International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery
Fu M, Zhao R, Cao Y, Nan Y, Fan L, Liu Z
Gynecological cancers, including ovarian, cervical, and endometrial cancers, remain major contributors to female morbidity and mortality worldwide. Conventional treatments-surgery, chemotherapy, and radiotherapy-have improved outcomes, but advanced or recurrent disease is still associated with poor prognosis…
Read the article →Molecular medicine reports2026ReviewNon-viral Gene Delivery
Qin R, Hu X, Jiang W, Wang J, Zheng M, Zhang Z, Et Al.
Genetic epilepsy, for which the molecular mechanisms are relatively well defined in numerous monogenic forms, represents an attractive model for the transition from symptomatic seizure control to mechanism‑driven correction. However, gene therapy strategies differ in their mechanisms of action, adaptability to…
Read the article →MedComm2026ReviewNon-viral Gene DeliveryDrug Delivery
Kamra K, Gaur S, Singh J
Respiratory diseases remain major causes of morbidity and mortality; however, inadequate pulmonary drug exposure and systemic toxicity continue to limit treatment efficacy. Inhaled nanomedicines offer opportunities for localized, sustained, and targeted therapy. This review examines how disease biology informs…
Read the article →European journal of haematology2026ReviewNon-viral Gene DeliveryDrug Delivery
Morabito F, Martino Ea, Bruzzese A, Amodio N, Caserta S, Lucia E, Et Al.
mRNA-based vaccines are emerging as a promising platform for cancer immunotherapy, including in hematologic malignancies. Current vaccine development has largely focused on antigen selection, mRNA engineering, lipid nanoparticle (LNP) formulation, and combination with established immunotherapies. However, increasing…
Read the article →Expert opinion on drug delivery2026ReviewDrug Delivery
Gelperina S, Wacker Mg
Apolipoprotein E (apoE) plays a context-dependent role in nanomedicine for central nervous system drug delivery. It can facilitate cerebral endothelial recognition and increase brain exposure in nanoparticle systems while simultaneously promoting hepatic uptake, challenging its traditional interpretation as a…
Read the article →Pharmaceutics2026ReviewDrug Delivery
Syed Hashim Sa
Clinical translation of lipid nanomedicines in oncology is limited by biological barriers and by an interpretive challenge: tumour accumulation and cellular uptake are often used as proxies for delivery even when pharmacologically competent cargo, meaning cargo capable of producing its intended molecular effect, has…
Read the article →International journal of molecular sciences2026ReviewNon-viral Gene DeliveryDrug Delivery
Rachamala Hk, Angom Rs, Marepally S
In recent years, lipid nanoparticles (LNPs) have shown great promise as highly flexible delivery systems for cancer vaccines, which enable effective cargo delivery and allow for controlling their distribution, cell-targeting ability and immunogenicity. Innovations in ionizable lipid chemistry, biodegradable…
Read the article →International journal of pharmaceutics2026ReviewNon-viral Gene DeliveryDrug Delivery
Shin Y, Lee S, Nguyễn Ánh Nt, Chung M
Lipid nanoparticles (LNPs) represent clinically validated non-viral platforms for nucleic acid delivery, yet expanding their application toward precision gene therapy demands more than efficient particle formulation or tissue accumulation. Functional delivery requires navigating a sequential biological cascade…
Read the article →Expert opinion on drug delivery2026ReviewNon-viral Gene DeliveryDrug Delivery
Wang N, Meng L, Shi Jx, Bartneck M
Small interfering RNA (siRNA) has progressed from an experimental gene-silencing tool to an established therapeutic modality through advances in chemical modification and delivery. Lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc)-siRNA conjugates have driven this clinical translation, particularly for…
Read the article →International journal of nanomedicine2026ReviewDrug Delivery
Gharatape A, Alikhanian A, Verdi J, Choonara Ye, Faridi-Majidi R
Although therapeutic opportunities beyond the scope of either field alone are offered by the combination of immune cell treatment and nanotechnology, a dominant nanoparticle design for immune-cell engineering has not been yielded by two decades of research. Here, it is contended that this lack of advancement is the…
Read the article →Frontiers in pharmacology2026ReviewNon-viral Gene DeliveryDrug Delivery
Rachamala Hk, Atla S, Angom Rs
Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated…
Read the article →Advances in Colloid and Interface Science2026ReviewNon-viral Gene DeliveryDrug Delivery
D Zhi, A Halemaimaiti, B Dai, H Li, H Wang, Z Zhang, J Yu, S Zhang
This review examines how lipid structure and formulation affect the delivery of DNA, mRNA and siRNA by lipid nanoparticles, while assessing tissue targeting, safety and clinical translation challenges.
Read the article →BioDrugs2026ReviewNon-viral Gene DeliveryDrug Delivery
U Iqbal, Rw Hwang, Wj Costain
A review of blood–brain barrier transport mechanisms and emerging lipid nanoparticle strategies for carrying nucleic acid and other complex therapies into the central nervous system.
Read the article →Small2025ReviewNon-viral Gene DeliveryDrug Delivery
S Sarmah, S Baidya, M De
This review surveys lipid nanoparticle composition, ionisable lipid synthesis and strategies to target delivery of fragile RNA therapeutics while addressing tissue selectivity and immune activation.
Read the article →Molecular Therapy Methods & Clinical Development2025ReviewNon-viral Gene Delivery
Ca Brimacombe, Ja Kulkarni, Mhy Cheng, K An, D Witzigmann, Pr Cullis
A review of the physical principles and development history behind siRNA lipid nanoparticles for liver gene silencing and mRNA lipid nanoparticles for protein expression.
Read the article →Nature Reviews Drug Discovery2024ReviewNon-viral Gene DeliveryDrug Delivery
Pr Cullis, Pl Felgner
This historical review traces lipid-based gene delivery from cationic lipoplexes to ionisable lipid nanoparticles, connecting foundational research with approved mRNA vaccines and siRNA therapy.
Read the article →